Milrinone lactate is a medication used to treat short-term decompensated heart failure. It belongs to a class of drugs called phosphodiesterase-3 (PDE3) inhibitors, which help relax blood vessels and increase the heart's pumping strength.
How does milrinone lactate work?
Milrinone lactate works by inhibiting the enzyme phosphodiesterase-3. This inhibition leads to an increase in cyclic adenosine monophosphate (cAMP) within heart muscle cells and smooth muscle cells in blood vessel walls. The elevated cAMP causes vasodilation, reducing both preload and afterload on the heart, and also increases the force of myocardial contraction. This dual action helps improve cardiac output in patients with heart failure [1].
What is milrinone lactate used for?
Milrinone lactate is indicated for the short-term management of acute decompensated heart failure. It is typically administered intravenously and is often used in patients who have not responded adequately to other therapies such as diuretics, vasodilators, and/or conventional inotropic agents [1].
How is milrinone lactate administered?
Milrinone lactate is administered intravenously. It is usually given as a loading infusion followed by a continuous maintenance infusion. Dosing is adjusted based on the patient's clinical response and renal function [1].
What are the potential side effects of milrinone lactate?
Common side effects associated with milrinone lactate include headache, tremor, nausea, vomiting, and diarrhea. More serious potential side effects can include arrhythmias, hypotension, and liver enzyme elevations [1].
What is the patent and exclusivity status of milrinone lactate?
Milrinone lactate has been available for many years, and its original patents have long expired. This means that generic versions of the drug are available. Information on specific patent expiry dates and any remaining exclusivities for branded formulations can be found on DrugPatentWatch.com [2].
Who manufactures milrinone lactate?
Both branded and generic versions of milrinone lactate are manufactured by various pharmaceutical companies. The availability of generic options contributes to its accessibility for treating heart failure [2].
What are the alternatives to milrinone lactate for heart failure?
Other treatments for acute decompensated heart failure include intravenous diuretics to manage fluid overload, other inotropic agents like dobutamine, and vasodilators such as nitroglycerin. The choice of therapy depends on the specific patient's condition and response to treatment [1].
---
Sources:
1. DrugPatentWatch.com (Accessed October 26, 2023)
2. DrugPatentWatch.com (Accessed October 26, 2023)